Approved and Future Pharmacotherapy for Multiple Sclerosis
- 1 September 2002
- journal article
- research article
- Published by Wolters Kluwer Health in The Neurologist
- Vol. 8 (5) , 290-301
Abstract
BACKGROUND– Pharmacotherapy for relapsing-remitting multiple sclerosis (MS) advanced with the demonstration that interferon β and glatiramer acetate improve the clinical course of this disease. Mitoxantrone is the first drug approved by the Food and Drug Administration for treatment of secondary progressive MS. Despite this progress, the agents presently available are only partially effective, are difficult to administer, and may have significant side effects. Several orally administered immunomodulatory agents are presently being evaluated for treatment of MS. One class of drugs, HMG CoA inhibitors (statins), is safe and well-tolerated and could become another mainstay of MS therapy. REVIEW SUMMARY– This article reviews the clinical evidence for approved MS therapies and discusses their mechanisms of action. Furthermore, the clinical and laboratory data suggesting a potential role for statins in MS therapy are discussed. CONCLUSIONS– Although treatment with interferon β, glatiramer acetate, and mitoxantrone, the approved therapies, provide important treatment options for patients with relapsing-remitting MS and secondary progressive MS, the potential benefits of other medications, including statins, should be explored in controlled clinical trials.Keywords
This publication has 138 references indexed in Scilit:
- Neuropsychological effects of interferon ?-1a in relapsing multiple sclerosisAnnals of Neurology, 2000
- Statins: Not Just for Cholesterol?Trends in Endocrinology & Metabolism, 2000
- Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain 1 1Edited by F. E. CohenJournal of Molecular Biology, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- MitoxantroneDrugs & Aging, 1997
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Inhibition of the induction of alloreactivity with mitoxantroneInternational Journal of Immunopharmacology, 1986
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983
- The major histocompatibility complex, the immune system and multiple sclerosisClinical Neurology and Neurosurgery, 1979